Erica Schlesinger1, Natalie Ciaccio2, Tejal A Desai3. 1. University of California, Berkeley-University of California San Francisco Graduate Program in Bioengineering, CA, USA. 2. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA; BioMarin Pharmaceutical Inc., Novato, CA, USA. 3. University of California, Berkeley-University of California San Francisco Graduate Program in Bioengineering, CA, USA; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Abstract
PURPOSE: To define empirical models and parameters based on theoretical equations to describe drug release profiles from two polycaprolactone thin-film drug delivery systems. Additionally, to develop a predictive model for empirical parameters based on drugs' physicochemical properties. METHODS: Release profiles from a selection of drugs representing the standard pharmaceutical space in both polycaprolactone matrix and reservoir systems were determined experimentally. The proposed models were used to calculate empirical parameters describing drug diffusion and release. Observed correlations between empirical parameters and drug properties were used to develop equations to predict parameters based on drug properties. Predictive and empirical models were evaluated in the design of three prototype devices: a levonorgestrel matrix system for on-demand locally administered contraception, a timolol-maleate reservoir system for glaucoma treatment, and a primaquine-bisphosphate reservoir system for malaria prophylaxis. RESULTS: Proposed empirical equations accurately fit experimental data. Experimentally derived empirical parameters show significant correlations with LogP, molecular weight, and solubility. Empirical models based on predicted parameters accurately predict experimental release data for three prototype systems, demonstrating the accuracy and utility of these models. CONCLUSION: The proposed empirical models can be used to design polycaprolactone thin-film devices for target geometries and release rates. Empirical parameters can be predicted based on drug properties. Together, these models provide tools for preliminary evaluation and design of controlled-release delivery systems.
PURPOSE: To define empirical models and parameters based on theoretical equations to describe drug release profiles from two polycaprolactone thin-film drug delivery systems. Additionally, to develop a predictive model for empirical parameters based on drugs' physicochemical properties. METHODS: Release profiles from a selection of drugs representing the standard pharmaceutical space in both polycaprolactone matrix and reservoir systems were determined experimentally. The proposed models were used to calculate empirical parameters describing drug diffusion and release. Observed correlations between empirical parameters and drug properties were used to develop equations to predict parameters based on drug properties. Predictive and empirical models were evaluated in the design of three prototype devices: a levonorgestrel matrix system for on-demand locally administered contraception, a timolol-maleate reservoir system for glaucoma treatment, and a primaquine-bisphosphate reservoir system for malaria prophylaxis. RESULTS: Proposed empirical equations accurately fit experimental data. Experimentally derived empirical parameters show significant correlations with LogP, molecular weight, and solubility. Empirical models based on predicted parameters accurately predict experimental release data for three prototype systems, demonstrating the accuracy and utility of these models. CONCLUSION: The proposed empirical models can be used to design polycaprolactone thin-film devices for target geometries and release rates. Empirical parameters can be predicted based on drug properties. Together, these models provide tools for preliminary evaluation and design of controlled-release delivery systems.
Authors: Alessandro Grattoni; Haifa Shen; Daniel Fine; Arturas Ziemys; Jaskaran S Gill; Lee Hudson; Sharath Hosali; Randy Goodall; Xuewu Liu; Mauro Ferrari Journal: Pharm Res Date: 2010-07-01 Impact factor: 4.200
Authors: Brooke Winner; Jeffrey F Peipert; Qiuhong Zhao; Christina Buckel; Tessa Madden; Jenifer E Allsworth; Gina M Secura Journal: N Engl J Med Date: 2012-05-24 Impact factor: 91.245
Authors: David S Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali Journal: Nucleic Acids Res Date: 2007-11-29 Impact factor: 16.971
Authors: William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai Journal: Drug Deliv Transl Res Date: 2017-12 Impact factor: 4.617
Authors: Erica Schlesinger; Daniel Johengen; Ellen Luecke; Ginger Rothrock; Ian McGowan; Ariane van der Straten; Tejal Desai Journal: Pharm Res Date: 2016-03-14 Impact factor: 4.200
Authors: Jean Kim; Max Kudisch; Sri Mudumba; Hiroyuki Asada; Eri Aya-Shibuya; Robert B Bhisitkul; Tejal A Desai Journal: Invest Ophthalmol Vis Sci Date: 2016-08-01 Impact factor: 4.799
Authors: Leah M Johnson; Sai Archana Krovi; Linying Li; Natalie Girouard; Zach R Demkovich; Daniel Myers; Ben Creelman; Ariane van der Straten Journal: Pharmaceutics Date: 2019-07-04 Impact factor: 6.321
Authors: Linying Li; Leah M Johnson; Sai Archana Krovi; Zach R Demkovich; Ariane van der Straten Journal: Pharmaceutics Date: 2020-11-05 Impact factor: 6.321